Includes ESG Management Status and Achievements Across Environmental, Social, and Governance Sectors Aiming to Become a Sustainable Healthcare Company that Creates Social Value ILDONG Pharmaceutical (CEO Woongsup Yun) has published its 2025 Sustainability Report, outlining key aspects and directions of its ESG (Environmental, Social, and Governance) management, with the goal of realizing its vision of becoming a “sustainable healthcare company that creates social value.” The company explained that the report was published to transparently disclose major activities, achievements, and mid-to-long-term strategies related to ESG management, and to actively engage with stakeholders. This report covers the period from January to December 2024 and is structured around the company’s: ESG management framework and performance, Status in each ESG category (Environment, Social, Governance), Related data and appendices. It was prepared in accordance with major ESG standards and guidelines, including the GRI Standards, TCFD, and SASB. In addition, the report includes company-wide activities, results, and mid-to-long-term implementation plans for five key ESG issues, which were identified through stakeholder engagement and materiality assessment: New product and new business development Human resource enhancement Human rights management Quality and safety management Climate crisis response In the environmental sector, ILDONG focused on addressing climate change and carbon emissions. In 2024, it installed a solar power generation system at its Cheongju plant and participated in biodiversity conservation campaigns. In the social sector, the company reinforced its efforts both internally and externally—strengthening talent and human rights management, occupational safety and health, and corporate culture, while also engaging in community contributions such as donations and sponsorships, and enhancing quality management. In terms of governance, ILDONG worked to enhance transparency and strengthen communication and trust with stakeholders. Starting last year, the company expanded its disclosure of governance-related information, including the publication of a governance report. It also significantly improved its compliance with core governance indicators, in line with its commitment to responsible management and increasing shareholder value and rights. ILDONG Pharmaceutical stated that it will continue to strengthen and advance its ESG management practices across the organization, in order to effectively respond to market conditions and risks, meet stakeholder expectations, and grow into a sustainable company with a virtuous business cycle.

Over 80 Respiratory Medicine Specialists from Across Korea Attend to Share the Latest Insights in ILD ILDONG Pharmaceutical (CEO Woongsup Yun) announced on the 28th Apr, 2025 that it successfully held a launch symposium for its interstitial lung disease (ILD) treatment, Cuninta Tab. (ingredient: Nintedanib). The event was held on 26–27  April 2025 at the Gravity Josun Seoul Pangyo hotel in Seongnam, Gyeonggi Province, and was attended by more than 80 respiratory medicine specialists from across the country. Notably, Professor Dong Soon Kim, Professor at the University of Ulsan College of Medicine and a recognized expert in the ILD field both domestically and internationally, also participated and added prestige to the event. In his congratulatory remarks, Professor Kim stated, “In the past, due to a lack of research data, treatment options, and clinical experience regarding ILD, many unfortunate situations occurred in clinical practice. However, since the 2010s, thanks to the efforts of medical professionals and pharmaceutical companies, the path for patient treatment has broadened. I hope to see continued interest in the research, development, and distribution of therapies in the ILD field.” The symposium focused on sharing the latest knowledge on the treatment of interstitial lung diseases, such as progressive pulmonary fibrosis (PPF), for which Nintedanib is expected to be covered by national health insurance. Progressive pulmonary fibrosis (PPF) refers to a group of non-idiopathic pulmonary fibrosis (non-IPF ILDs) that show rapid progression of lung fibrosis despite appropriate treatment. PPF is known to have a poor prognosis, making early detection and proactive treatment crucial. The special lecture session consisted of four topics related to ILD and its treatments. Professor Man Pyo Jung of Samsung Medical Center served as the chair, and speakers included Professor Yang Jin Jegal of Ulsan University Hospital, Professor Ju Hun Park of Ajou University Hospital, Professor Hyun Kyung Lee of Busan Paik Hospital, and Professor Jin Woo Song of Asan Medical Center in Seoul. Professor Hyun Kyung Lee, who presented on “Managing Adverse Effects of Nintedanib and Patient Treatment Strategies,” emphasized that “Although Nintedanib is currently recommended for use in PPF, managing side effects from the patient's perspective is also essential.” She added, “Cuninta is in tablet form, which reduces the risk of residue in the oral mucosa, and the small pill size allows for quicker passage through the esophagus.” She also noted, “It is impressive that the product is packaged in PTP aluminum blister packs that block heat and moisture, demonstrating thoughtful consideration for patient convenience.” ILDONG Pharmaceutical plans to leverage its long-standing academic network and marketing capabilities in the pulmonary disease field, along with its newly launched respiratory product lineup including Cuninta, to actively expand its market presence. The company also reaffirmed its commitment to improving patient treatment outcomes and quality of life.

iLeadBMS, a spin-off biotech from Ildong Pharmaceutical Group, announced that it has received a notification from the US Food and Drug Administration (FDA) that its IL21120033, a first-in-class CXCR7 Agonist, has been granted Orphan Drug Designation (ODD) for treatment of idiopathic pulmonary fibrosis (IPF).  IPF is a rare lung disease characterized by progressive fibrosis of lung parenchyma, with a less than 40% survival rate five years after diagnosis. According to the National Institutes of Health, IPF affects about 100,000 people in the United States and approximately 30,000 to 40,000 new cases are diagnosed each year. Unfortunately, IPF remains an incurable and fatal disease despite the use of approved antifibrotic drugs. iLeadBMS is developing IL21120033 to address this high unmet medical need.  CXCR7 is a key mediator in signal transduction amplifying fibrosis and inflammation. CXCR7 selectively binds to chemokine ligand CXCL12, targeting various pathways associated with fibrosis, inflammation, tissue repair, and angiogenesis. This makes it an ideal therapeutic target for treating fibrotic diseases, and iLeadBMS plans to develop IL21120033 as an anti-fibrotic agent for various organs including the lung, liver, heart, kidney, and skin.  IL21120033 has exhibited high selectivity for CXCR7 without binding to other chemokine receptors and demonstrated promising pharmacokinetics in mice and rats when orally administered. In a bleomycin-induced pulmonary fibrosis model, IL21120033 showed dose-dependent improvements in the Ashcroft score, confirming its potentially superior anti-fibrotic efficacy compared to the standard therapy. Based on these results the FDA has granted ODD for IPF.  “We are very pleased to receive the Orphan Drug Designation from the FDA for IL21120033 for the treatment of IPF,” said Dr. Yoon-seok Lee, CSO of iLeadBMS. “This provides solid support for the development of IL21120033 for IPF as it has consistently demonstrated strong anti-fibrotic efficacy in several IPF animal models.”  iLeadBMS plans to complete the IND-enabling GLP toxicity studies this year.   About iLeadBMS Established in 2020 as a spin-off from Ildong Pharmaceuticals, iLeadBMS specializes in the discovery and development of novel drugs with therapeutic focus in oncology, autoimmune and fibrotic diseases. For more information, please visit https://www.ileadbms.com/ or https://www.linkedin.com/company/104793817.     About IL21120033 IL21120033 is a first-in-class CXCR7 agonist that activates CXCR7 receptor which binds and reduces CXCL12, a key pro-inflammatory factor under pathological conditions such as inflammation and autoimmune diseases. CXCR7 agonist also indirectly inhibits CXCR4-CXCL12 signaling to prevent fibrosis and inflammation. Additionally, CXCR7 agonist activates β-arrestin signal which can promote regeneration and cell survival, making it a potentially disease modifying agent. iLeadBMS is developing IL21120033 for various autoimmune and fibrotic diseases where standard therapies are lacking or suboptimal.

Ildong Pharmaceutical Participates in ‘CPhI Worldwide 2024,’ Aiming to Expand Global Markets and Diversify Business Exploring Export Opportunities for Cardiovascular Combination Drugs, Oncology and Antibiotics, and CMO Partnerships Highlighting Diabetes and Obesity Drug ‘GLP-1’ and Peptic Ulcer Treatment ‘P-CAB’   Ildong Pharmaceutical(CEO Woongsup Yun), participated in CPhI Worldwide 2024, promoting its active pharmaceutical ingredients (APIs), finished drugs, novel drug candidates, core technologies, and manufacturing infrastructure while seeking new business opportunities. CPhI Worldwide, the largest pharmaceutical and biotech industry exhibition, took place from October 8 to 10 in Milan, Italy. Ildong set up an exhibition booth in the Korea Pavilion to showcase its offerings and conducted numerous partnering meetings with companies to explore business development and collaboration opportunities. The company presented its global business portfolio, including combination drugs (Fixed Dose Combination) like Telostop, Twotops, and Droptop, which are already being exported to Southeast Asia, as well as oncology drugs, antibiotics, and wound care dressings such as Meditouch. Ildong also emphasized its capabilities in contract manufacturing (CMO) using its GMP-certified facilities dedicated to antibiotics and oncology drugs. Furthermore, it sought to establish partnerships for the commercialization of its proprietary drug candidates. Ildong Pharmaceutical has a robust pipeline in areas such as: Metabolic Disorders Gastrointestinal Diseases Degenerative Diseases Ongoing efforts include clinical development and commercialization of promising drug candidates. During the event, the company garnered particular interest in: ID110521156, an oral synthetic drug candidate targeting GLP-1 (Glucagon-Like Peptide-1) receptors for diabetes and obesity. ID120040002, a peptic ulcer treatment from the P-CAB (Potassium-Competitive Acid Blocker) class. ID119040338, a Parkinson’s disease treatment acting as a dual antagonist of adenosine A1 and A2A receptors. ID119031166, a candidate for the treatment of metabolic-associated steatohepatitis (MASH). Ildong representative stated, “We aim to expand our business into broader healthcare fields, including functional foods and cosmetics, in addition to our existing pharmaceutical products. Furthermore, we plan to diversify our global strategy through new drug pipeline collaborations, licensing-out opportunities, and CMO projects.”

Showcasing ESG Achievements and Future Corporate Vision Reaffirming Commitment to Becoming a "Sustainable Global Healthcare Company Ildong Pharmaceutical, led by CEO Yun Woongsup, has published its 2024 Sustainability Management Report, outlining the company’s current ESG (Environmental, Social, and Governance) initiatives and its future direction. The company explained that the report was designed to transparently disclose key ESG activities, achievements, and medium- to long-term strategies to stakeholders while actively fostering communication. The report, which covers activities from January to December 2023, consists of: Company Overview ESG Management Framework and Achievements ESG Status by Sector (Environmental, Social, and Governance) Related Data and Appendices The content adheres to the GRI Standards, an international sustainability reporting guideline. Through stakeholder feedback, the company identified five key sustainability issues: Development of competitive new products Climate change response and establishment of a carbon-neutral framework Strengthening anti-corruption compliance Talent acquisition and enhancement of human resource capabilities Improvement of product quality and safety management The report highlights Ildong Pharmaceutical's efforts, initiatives, and achievements in these areas. Recognizing the global urgency of climate change, Ildong has proposed actionable measures in response. The company has committed to reducing greenhouse gas emissions by 20% by 2030 and achieving carbon neutrality by 2050. This strategy includes analyzing the impact of climate-related risks on business operations through a "Climate Change Response Scenario Analysis." Under its corporate philosophy of contributing to "the health and happiness of humanity," Ildong has prioritized ESG management. Since establishing its ESG Committee in 2017, the company has expanded its ESG efforts by creating a dedicated ESG department and consultative body. These organizations integrate ESG principles into management indicators, policies, and operational strategies. The company actively participates in various social contribution activities, including donations and sponsorships. Recently, Ildong launched the "Ildong-i Volunteer Group" to promote environmental protection campaigns and activities supporting socially vulnerable groups. This initiative emphasizes employee-driven participation. Ildong Pharmaceutical has reaffirmed its commitment to becoming a "Sustainable Global Healthcare Company." The company aims to adapt effectively to external market challenges, maximize corporate value, and meet stakeholder expectations by advancing its ESG management practices.